MOTS-c Peptide: Research, Side Effects, Legality & Cost

MOTS-c: the quick answer

What it is: MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, discovered in 2015. It is studied for its role in metabolism, insulin sensitivity and exercise adaptation.
Evidence level: Cell and animal studies. No completed human trial of unmodified MOTS-c had been published as of mid-2026; an analogue, CB4211, has been in early-phase trials.
Status: Not an approved medicine anywhere. In the US, HHS has said it does not intend to take enforcement action against state-licensed pharmacies that compound MOTS-c on its own, for subcutaneous or intramuscular injection, on a patient-specific prescription. This is interim enforcement discretion, not FDA approval.

This page is informational and does not diagnose, prescribe, or recommend therapies.

What is MOTS-c?

MOTS-c stands for mitochondrial open reading frame of the twelve S rRNA type-c. It is a peptide of 16 amino acids encoded within mitochondrial DNA rather than in the nuclear genome. That places it in a class called mitochondrial-derived peptides.

Since its discovery in 2015 MOTS-c has been studied for roles in metabolic regulation, insulin sensitivity and exercise adaptation, mostly in cells and animals. No completed human trial of unmodified MOTS-c had been published as of mid-2026; an analogue, CB4211, has been in early-phase trials, and results for an analogue are not results for MOTS-c itself.

MOTS-c is thought to act on AMPK signalling, a central regulator of cellular energy. That is the basis of the claims about metabolic health, exercise performance and longevity. The mechanism is real in laboratory settings; what does not yet exist is a completed human trial of unmodified MOTS-c (none had been published as of mid-2026) showing those benefits in people.

Because the body makes MOTS-c itself, it is often marketed as natural. The body producing a peptide says nothing about the effects of injecting a synthetic version, a question no completed human trial has answered.

What MOTS-c is used for

Longevity and metabolic-health programs, where it is one of the most-referenced newer peptides.
Performance and exercise-adaptation discussions, the context that led WADA to name it on the prohibited list.
Mitochondrial-health positioning alongside NAD+ and related compounds.
US compounding on prescription, by subcutaneous or intramuscular injection only, within the interim HHS policy (see legal status below).

Legal status and the US policy's conditions

Claimed benefits vs what the evidence shows

The claims people most often search for about MOTS-c, set against the research. The evidence level names the kind of study a claim rests on: cell (laboratory) studies, animal studies, human studies, or none. Educational only, not medical advice.

Overall: Preclinical only for administration. Cell and animal studies support the mechanism, but as of mid-2026 no completed human clinical trial of unmodified MOTS-c had been published. An analogue, CB4211, has been in early-phase trials. Human data: None completed for administration of the peptide itself; observational and mechanistic human data only.

Claim	Evidence level	What the evidence shows
“Speeds up metabolism and burns fat”	Cell and animal	Those effects come from animal and cell studies. No completed human trial of unmodified MOTS-c had been published as of mid-2026, so fat-loss claims in people are extrapolation, not evidence.
“Improves insulin sensitivity and blood sugar”	Cell and animal	Insulin sensitivity is one of the roles MOTS-c has been studied for, mostly in cells and animals. A completed human trial of giving the peptide has not shown it.
“An exercise mimetic that boosts endurance”	Cell and animal	The exercise-adaptation findings are preclinical. Whatever it is used for, WADA named it on the prohibited list from January 1, 2024, so tested athletes face strict-liability violations.
“A longevity peptide that slows aging”	None in humans	Longevity interest rests on the AMPK mechanism and preclinical work. No completed human trial has tested MOTS-c for aging.
“A natural mitochondrial hormone, so it's harmless”	Not established	The body producing a peptide endogenously says nothing about the safety of injecting synthetic versions at supraphysiological doses, a question no completed human trial has answered.

MOTS-c side effects and risks

What is known

No side-effect profile has been established for MOTS-c in people, because no completed human trial of unmodified MOTS-c had been published as of mid-2026.

What is not known

Its efficacy and safety in people are unknown. Dosing, long-term effects and risks are extrapolated from preclinical work.

Product quality and gray-market vials

Outside the US prescription route, any MOTS-c bought is gray-market product with unverified identity and purity. A product compounded on prescription under the US policy has to meet its quality conditions; a 'research use only' vial meets none of them. The policy's conditions are under legal status.

Who should take particular care

Tested athletes. MOTS-c is explicitly named on the WADA prohibited list (S4, metabolic modulators), banned at all times, with strict liability.
Anyone with a metabolic goal. Approved, evidence-based options for that goal should be discussed with a clinician first.
Anyone offered MOTS-c in a blend. A blend is outside the US policy.

MOTS-c dosage: why this page gives no dose

Searches for a MOTS-c dosage are looking for a number, and there is no approved one: MOTS-c is not approved anywhere, and no completed human trial has established a dose. Under the US policy, a compounded MOTS-c product (subcutaneous or intramuscular injection) is made for one named patient on a prescription, so the amount and schedule are set by the prescriber.

MOTS-c vials are labeled in milligrams of peptide and nothing about volume, so the same vial can give very different figures on a syringe depending on how much water is added. The calculator below does that arithmetic and nothing more.

Peptide Clinic Finder does not give doses, and this page has no dosing chart. If you have been prescribed it, the amount, form and schedule are the prescriber's and the pharmacy's instructions, not a figure from a website.

MOTS-c dosage calculator: Turns a prescribed amount into mL and U-100 syringe units for a MOTS-c vial. Maths only: no dosing chart and no suggested dose.
peptide calculator: The same arithmetic for any reconstituted vial, with a full reconstitution chart.

Is MOTS-c legal? US, UK and sport status

United States

Not FDA-approved. Under the HHS interim policy announced on October 28, 2026 and published in the Federal Register on October 30, 2026, state-licensed pharmacies, federal facilities and licensed physicians may compound MOTS-c acetate for an individual prescription, as the only active ingredient, for subcutaneous or intramuscular injection, if the policy's conditions are met. Interim enforcement discretion that HHS may revisit, not approval (checked October 30, 2026).

Source: FDA: Drugs@FDA (openFDA) — no matching approved product · United States · Status verified August 31, 2026

Source: HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Docket HHS-OASH-2026-0496), Federal Register public inspection copy · United States · Published October 30, 2026

What the policy requires: for MOTS-c, the covered form is MOTS-c acetate, as a subcutaneous or intramuscular injection. The other conditions in Appendix B are the same for all six peptides it lists: a licensed clinician prescribes it for an individual patient; a state-licensed pharmacy compounds it from bulk ingredient made by an FDA-registered, CGMP manufacturer with a certificate of analysis; the product contains no other active ingredient; the label says it is a compounded drug product, not for resale; and serious adverse events are reported to FDA's MedWatch and to the states involved. The policy does not cover 503B outsourcing facilities, “research use only” products or dietary supplements. Our guide to the October 2026 US peptide policy sets out each condition and its source.

Source: HHS: 503A peptide enforcement discretion policy, Appendix B: conditions and covered routes of administration · United States · Published October 28, 2026 · Accessed October 30, 2026

The same interim policy covers five other peptides, each only on its own and by its own route: KPV peptide (covered for topical or oral use only), TB-500 peptide (covered by subcutaneous or intramuscular injection), Semax peptide (covered for intranasal use only), Epitalon peptide (covered by subcutaneous or intramuscular injection, dispensed in intermittent courses) and BPC-157 peptide (covered by subcutaneous or intramuscular injection, by mouth or on the skin).

United Kingdom

Not a licensed UK medicine. No current UK marketing authorization was found for MOTS-c in the MHRA Products register as of August 31, 2026. The HHS policy is US only and changes nothing in the UK or Ireland.

Source: MHRA: MHRA Products register · United Kingdom · Status verified August 31, 2026

Sport (anti-doping)

Explicitly named on the WADA prohibited list (S4, metabolic modulators), banned in sport at all times, with strict liability for athletes.

Source: WADA: International Standard — Prohibited List 2026 · International (WADA Code signatories) · In force January 1, 2026

Source: WADA: World Anti-Doping Code 2021, Article 2.1.1 · International (WADA Code signatories) · In force January 1, 2021

Last reviewed October 30, 2026. Regulatory status can change. Always confirm the current position with a qualified clinician.

Questions to ask a prescriber or clinic about MOTS-c

No completed human trials of MOTS-c exist. What is the basis for recommending it to me?
Am I subject to any sports testing? If so, why are we discussing a WADA-prohibited substance?
What approved, evidence-based options address my metabolic goals first?

What a credible provider tells you

A credible provider should say plainly that no completed human trials of MOTS-c administration exist.
Expect a clear statement that it is WADA-banned at all times. Any tested athlete must avoid it.
Be cautious of 'mitochondrial optimization' framing that implies proven human benefit.

Red flags

Claims of proven fat-loss, endurance, or longevity benefits in humans. That evidence does not exist yet.
No mention of the explicit WADA ban to athletic clients.
Framing the 2026 HHS compounding policy, or the earlier advisory-committee vote, as approval.

MOTS-c cost and US availability

There is no approved product and no completed human efficacy trial. In the US, since the October 2026 HHS interim policy, some telehealth services price a compounded single-ingredient MOTS-c per month, if prescribed; elsewhere any price is a gray-market price for an unproven compound. Either way, the question is not cost but whether the purchase makes sense at all yet. See the peptide therapy cost guide. For what the October 2026 HHS policy changed for the six peptides it covers, read our US guide to peptide prescriptions under the new compounding policy.

US telehealth prices for compounded MOTS-c are shown to US visitors. It is not a licensed medicine in the UK.

Frequently asked questions about MOTS-c

What is MOTS-c used for?

MOTS-c is referenced in longevity, metabolic-health and exercise-performance contexts, on the strength of cell and animal studies of metabolism, insulin sensitivity and exercise adaptation. No completed human trial of administering it has tested those uses.

Does MOTS-c work?

In people, that is not known. The mechanism (AMPK signalling) is real in laboratory settings, but as of mid-2026 no completed human trial of administering unmodified MOTS-c had been published, so human benefit claims rest on preclinical research.

Is MOTS-c safe?

Its safety in people is unknown. No completed human trial of unmodified MOTS-c had been published as of mid-2026, so dosing, long-term effects and risks are extrapolated from preclinical work, and gray-market products add unverified identity and purity. Tested athletes also face strict-liability anti-doping consequences.

Is MOTS-c FDA approved?

No. It is not approved anywhere. No completed human trial of unmodified MOTS-c had been published as of mid-2026; an analogue, CB4211, has been in early-phase trials. The interim HHS compounding policy of October 2026 is enforcement discretion, not approval.

Is MOTS-c legal in the UK?

MOTS-c is not a licensed medicine in the UK: no current UK marketing authorization was found in the MHRA Products register as of August 31, 2026. The US compounding policy does not apply in the UK.

Why is MOTS-c banned in sport if it's unproven?

WADA bans substances on potential to enhance performance, not proof of it. MOTS-c was explicitly added to the prohibited list from January 1, 2024 under S4 (metabolic modulators) and is banned at all times, in and out of competition.

Is MOTS-c legal in the US?

Yes, within limits. After the FDA's advisory committee voted in July 2026 to recommend it, despite FDA staff advising against the move, HHS announced an interim policy on October 28, 2026 (published in the Federal Register on October 30) under which HHS does not intend to take enforcement action against state-licensed pharmacies that compound MOTS-c acetate for an individual prescription, as the only active ingredient, by subcutaneous or intramuscular injection, under set conditions. HHS says it does not grant FDA approval and that it may revisit the policy. MOTS-c remains banned in sport.

Does Peptide Clinic Finder sell or recommend MOTS-c?

No. Peptide Clinic Finder is an informational directory. We do not sell MOTS-c, provide medical advice, or recommend its use — we explain the real evidence state so you can make informed decisions with a licensed clinician.

Next step

Compare Providers and Next Steps

If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.

Compare Providers Get Matched Browse city clinics

Related MOTS-c pages

Move from peptide research into clinic comparisons, guides, and matching.

US peptide prescriptions after the HHS change MOTS-c dosage calculator: mL and syringe units Peptide calculator: reconstitution, dose and syringe units The Catalyst Clinic The Forest Lounge Medical Center Extend Medical HUM2N Reborne Longevity 360 MD Austin

Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.

Clinics offering MOTS-c

No clinics are currently tagged with this peptide. Explore related goals, conditions, and comparisons below.

Explore clinics by city

Miami peptide clinics Los Angeles peptide clinics New York peptide clinics All US locations Semaglutide Semaglutide vs tirzepatide

What to do next

Move from treatment research into provider comparison by choosing the next step that fits your buying journey. Some users want to compare programs first, while others want a faster route into matched options or local clinic discovery.

Compare Providers Get Matched Miami clinics Los Angeles clinics New York clinics